We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Rhythm Pharmaceuticals Inc (RYTM) USD0.001

Sell:$56.78 Buy:$64.78 Change: $0.55 (0.93%)
NASDAQ:0.16%
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$56.78
Buy:$64.78
Change: $0.55 (0.93%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$56.78
Buy:$64.78
Change: $0.55 (0.93%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Contact details

Address:
222 Berkeley Street, 12th Floor Boston
BOSTON
02116
United States
Telephone:
+1 (857) 2644280
Website:
www.rhythmtx.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RYTM
ISIN:
US76243J1051
Market cap:
$3.65 billion
Shares in issue:
61.46 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Meeker
    Chairman of the Board, President, Chief Executive Officer
  • Hunter Smith
    Chief Financial Officer, Treasurer
  • Pamela Cramer
    Chief Human Resource Officer
  • Jennifer Lee
    Executive Vice President, Head of North America
  • Yann Mazabraud
    Executive Vice President, Head of International
  • Alastair Garfield
    Chief Scientific Officer
  • Joseph Shulman
    Chief Technical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.